Ainos, Inc.
AIMDDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
interferon-alpha lozenges
Hepatitis C, Chronic
Interferon-alpha
Influenza A Virus Infection
Veldona,
Behcet Syndrome
Interferon alpha oral lozenge
Respiratory Tract Diseases
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
interferon-alpha lozenges | Phase 2 | Hepatitis C, Chronic | - | - |
Interferon-alpha | Phase 2 | Influenza A Virus Infection | - | - |
Veldona, | Phase 2 | Behcet Syndrome | - | - |
Interferon alpha oral lozenge | Phase 2 | Respiratory Tract Diseases | - | - |
Frequently asked questions
What is in Ainos, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Ainos, Inc.'s (AIMD) pipeline across Phase 2. Its lead program is interferon-alpha lozenges (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ainos, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Ainos, Inc. (AIMD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AIMD biotech catalysts?→
Add AIMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ainos, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.